|本期目录/Table of Contents|

[1]严鹏,李欣,齐连振,等.多沙普仑对比尼可刹米治疗COPD合并呼吸衰竭患者临床疗效[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):582-587.[doi:10.3969/j.issn.1672-271X.2021.06.005]
　YAN Peng,LI Xin,QI Lian-zhen,et al.Effect of doxapram versus nikzami in patients with COPD complicated with respiratory failure[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(6):582-587.[doi:10.3969/j.issn.1672-271X.2021.06.005]
点击复制

多沙普仑对比尼可刹米治疗COPD合并呼吸衰竭患者临床疗效()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年6期
页码:
582-587
栏目:
临床研究
出版日期:
2021-12-15

文章信息/Info

Title:
Effect of doxapram versus nikzami in patients with COPD complicated with respiratory failure
作者:
严鹏; 李欣; 齐连振; 代兆华
作者单位：054000邢台，邢台医学高等专科学校第二附属医院医务科（严鹏），重症医学科（李欣、齐连振、代兆华）
Author(s):
YAN Peng;  LI Xin;  QI Lian-zhen;  DAI Zhao-hua
(1.Department of Medical, 2. Department of Critical Care Medicine, the Second Affiliated Hospital of Xingtai Medical College, 054000 Xingtai, Hebei, China)
关键词:
多沙普仑; 尼可刹米; 慢性阻塞性肺疾病合并呼吸衰竭; 表面活性蛋白; Clara细胞分泌蛋白
Keywords:
doxapram;  nikzami; COPD combined with respiratory failure;  surfactant protein D;  clara cell secretory 16-KD protein
分类号:
R453.2
DOI:
10.3969/j.issn.1672-271X.2021.06.005
文献标志码:
A
摘要:
目的观察多沙普仑、尼可刹米不同呼吸兴奋剂治疗慢性阻塞性肺疾病（COPD）合并呼吸衰竭患者疗效及其对肺表面活性蛋白（SP-D）和Clara细胞分泌蛋白（CC16）表达情况的影响。方法选取2016年12月-2017年12月邢台医学高等专科学校第二附属医院收治的194例COPD合并呼吸衰竭患者，采用随机数字表法将患者分为多沙普仑组和尼可刹米组，每组97例；在常规治疗的基础上，尼可刹米组患者给予尼可刹米静脉滴注；而多沙普仑组给予多沙普仑静脉滴注。治疗一个疗程后对患者疗效进行评估，比较治疗前后患者血气分析指标、6 min步行试验结果和生活质量，检测治疗前后血清中SP-D与CC16含量，记录2组不良反应情况。结果多沙普仑组总有效率（94.84%）明显高于尼可刹米组（75.25%），差异有统计学意义（P<0.05）。治疗后2组患者PaO2、OI升高，PaCO2降低，多沙普仑组PaO2、OI显著高于尼可刹米组[（83.61±7.34）mmHg vs (72.65±6.85) mmHg，（298.67±21.34）mmHg vs (262.41±26.64）mmHg，P<0.01]，PaCO2显著低于尼可刹米组[（51.03±5.71）mmHg vs (35.10±6.22) mmHg，P<0.01]。多沙普仑组患者出院后3、6个月6 min步行距离高于尼可刹米组患者（P<0.05）。多沙普仑组出院后3、6个月生活质量优于尼可刹米组（P<0.05）。治疗1个疗程后2组患者血清SP-D降低、CC16升高，并且多沙普仑组SP-D低于尼可刹米组[（0.52±0.09）ng/mL vs (0.64±0.07）ng/mL,P<0.01]，而CC16水平高于尼可刹米组[（0.21±0.05）pg/mL vs (0.28±0.04）pg/mL,P<0.01]。多沙普仑组出院91例，尼可刹米组出院71例。多沙普仑组改有创通气率较尼可刹米组明显降低（P<0.05）。2组不良反应发生率比较差异无统计学意义（P>0.05）。结论多沙普仑较尼可刹米治疗COPD合并呼吸衰竭患者临床疗效更加明确，能够有效改善PaO2、PaCO2，提高患者远期生活质量，同时降低SP-D水平，提高CCL16表达水平，安全可靠，具有一定临床应用价值。
Abstract:
ObjectiveTo observe the effect of doxapron-assisted treatment of Chronic obstructive pulmonary disease (COPD) patients with respiratory failure and its effect on the expression of surfactant protein D (SP-D) and Clara cell secretory 16-kd protein (CC16).Methods194 patients with COPD and respiratory failure admitted to our hospital from December 2016 to December2017 were enrolled. Patients were divided into doxapram group and nikethamide group On the basis of conventional treatment, the nikethamide group received an intravenous infusion of nikethamide, while doxapram group was given intravenous infusion of doxapram, and 7 days was a course of treatment.After one course of treatment, the efficacy of the patients was evaluated, and the blood gas analysis index of the patients before and after treatment, the results of the 6 min walking test and the quality of life was compared. The contents of sp-d and CC16 in the serum before and after treatment were observed. Adverse reactions were recorded in both groups.ResultsThe total effective rate of doxapram group (94.84%) was significantly higher than that of nicothamide group (75.25%) (P<0.05). After treatment, PaO2 and OI increased and PaCO2 decreased in the two groups. PaO2 and OI in doxapram group were significantly higher than those in nicothamide group[（83.61±7.34）mmHg vs (72.65±6.85) mmHg，（298.67±21.34）mmHg vs (262.41±26.64）mmHg，P<0.01], and PaCO2 was significantly lower than those in nicothamide group[（51.03±5.71）mmHg vs (35.10±6.22) mmHg，P<0.01]. The 6-min walking distance in doxapram group was higher than that in nicothamide group at 3 and 6 months after discharge (P<0.05). The quality of life in doxapram group was better than that in nicothamide group at 3 and 6 months after discharge (P<0.05). After one course of treatment, serum SP-D decreased and CC16 increased in the two groups. SP-D in doxapram group was lower than that in nicothamide group[（0.52±0.09）ng/mL vs (0.64±0.07）ng/mL, P<0.01], while the level of CC16 was higher than that in nicothamide group[（0.21±0.05）pg/mL vs (0.28±0.04）pg/mL, P<0.01]. 91 of 97 patients in doxapram group were discharged, 71 of 97 patients in nicothamide group were discharged, 4 cases in doxapram group were changed to invasive ventilation, 23 cases in nicothamide group were changed to invasive ventilation (P<0.05). The incidence of adverse reactions was 13.14% in doxapram group and 16.49% in nicothamide group (P>0.05).ConclusionDoxapram is safe and effective in the treatment of patients with COPD and respiratory failure, which can improve the efficiency of treatment, improve PaO2, PaCO2 of patients, improve the long-term quality of life of patients, reduce the level of SP-D and improve the expression of CC16, reduce airway hyperresponsiveness of patients which is beneficial to their rehabilitation.

参考文献/References:

[1]李雪英, 胡苏萍, 陈国忠. 炎症反应与慢性阻塞性肺疾病相关肺动脉高压及其血液高凝状态的关系 [J]. 山东医药, 2017, 57(1): 71-73.
[2]刘海文,贵州汉族慢性阻塞性肺疾病患者Toll样受体1基因多态性与肺念珠菌感染及定植的相关性[J]. 医学研究生学报, 2019, 32(4):384-390.
[3]黄利民, 张炜, 孙兆瑞,等. 氨溴索雾化吸入治疗老年慢性支气管炎疗效及安全性的系统评价[J]. 东南国防医药, 2020, 22(2):165-171.
[4]Ban WH, Kang HH, Kim IK, et al. Clinical significance of nuclear factor erythroid 2-related factor 2 in patients with chronic obstructive pulmonary disease[J]. Korean J Intern Med, 2018, 33(4):745-752.
[5]Lopes LR, Ribeiro S, Figueiredo VP, et al. The overweight increases circulating inflammatory mediators commonly associated with obesity in young individuals[J]. Cytokine, 2018, 110（42）:169-173.
[6]罗明. 多沙普仑结合常规疗法治疗慢阻肺并发Ⅱ型呼吸衰竭的效果及对ACO2、SLC16的影响 [J]. 临床肺科杂志, 2017, 22(9): 1595-1598.
[7]中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)(一)[J]. 中华结核和呼吸杂志, 2013, 36(4):255-264.
[8]李玉华, 蔡旻, 高杉杉,等. 某院患者医院获得性肺炎的回顾性分析[J]. 东南国防医药, 2019,12(5):487-490.
[9]田家伟, 蔡丽婷, 侯昕珩. 呼吸训练器在稳定期慢性阻塞性肺疾病患者肺康复中的临床应用疗效分析[J]. 中国康复理论与实践, 2019, 34(6):295-298.
[10]毛文君, 陈静瑜, 郑明峰,等. 肺动脉高压对等待肺移植的慢性阻塞性肺疾病患者预后的影响[J]. 中华器官移植杂志, 2018, 39(9):553-558.
[11]郑相如, 刘茂茂, 袁媛, 等. 过表达细胞因子信号传导抑制蛋白1的树突状细胞过继免疫对COPD模型中T细胞相关因子的影响[J]. 医学研究生学报, 2019, 32(3):230-234.
[12]郑奇辉, 刘伟, 王书宝, 等. GABAA受体在七氟醚抑制新生大鼠延髓呼吸中枢吸气神经元放电中的作用[J]. 中华麻醉学杂志, 2018, 38(11):1311-1313.
[13]谭熙, 梁宗安. 不同呼吸兴奋剂联合无创正压通气治疗慢性阻塞性肺病合并呼吸衰竭的临床疗效[J]. 海军医学杂志, 2015, 36 (6):53-56.
[14]Jin Y， Peng LQ， Zhao AL. Hyperoxia induces the apoptosis of alveolar epithelial cells and changes of pulmonary surfactant proteins[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2):492-497.
[15]Ma X, Jiao X, Wu J, et al. The Function of Ophiocordyceps sinensis in Airway Epithelial Cell Senescence in a Rat COPD Model[J]. Can Respir J, 2018. doi: 10.1155/2018/6080348.
[16]李春华, 刘微丽. 血清HbA1c、sTREM-1与CC16联合检测对COPD患者病情程度变化的判定价值研究[J]. 河北医药, 2019, 41(10):56-59.
[17]周海. 重度COPD稳定期患者血清CC16、SP-D、MSP与患者肺功能、病情严重程度的关系[J]. 临床肺科杂志, 2019, 24(7):1168-1171.
[18]黄曼, 贾钦尧, 许冀, 等. 多沙普仑联合双水平气道正压通气治疗慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭患者的临床疗效[J]. 实用心脑肺血管病杂志, 2018, 26(1):114-117.

相似文献/References:

备注/Memo

备注/Memo:
基金项目：河北省邢台市科技计划项目（2019ZC341）
更新日期/Last Update: 2021-12-15